Latest Bio-Techne News & Updates
See the latest news and media coverage for Bio-Techne. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer and manufacturer of life-science reagents and instruments
bio-techne.com- Headquarters
- Minneapolis, United States
- Founded year
- 1976
- Company type
- Public company
- Number of employees
- 2,500–5,000
Last updated
Latest news about Bio-Techne
In short: Bio-Techne reported mixed fiscal 2026 results with flat revenue growth and margin expansion while celebrating its 50th anniversary and new leadership.
Company announcements
-
Bio-Techne releases Q3 FY2026 results
Revenue declines 2% to $311.4M. GAAP EPS rises to $0.32. Adjusted EPS falls to $0.53. Growth in large pharma and spatial biology.
-
Bio-Techne introduces streamlined brand architecture
It organizes technologies into R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™ to aid customer navigation from discovery to diagnostics.
-
Bio-Techne advances COMET platform with SPYRE panels and kits
These additions enhance modular workflow flexibility, sensitivity, and data quality in spatial biology ecosystem.
-
Bio-Techne launches revitalized San Jose innovation center
It features expanded lab space and cutting-edge technology to boost instrument, reagent, and software innovation. CEO Kim Kelderman celebrated the milestone at the ribbon-cutting.
Media coverage
-
Earnings call transcript: Bio-Techne Q3 2026 results show strategic focus By Investing.com
Bio-Techne Corporation reported its third-quarter fiscal 2026 earnings, revealing a slight miss on...
-
Bio-Techne expects Q4 organic growth approximately flat while targeting ~100 bps margin expansion
Q3 fiscal 2026 Management View "The Bio-Techne team continued to execute with discipline in a dynamic and uneven end market environment" and said results were...
-
Bio-Techne Declares Dividend
Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March...
-
Bio-Techne misses revenue estimates as US academic funding cuts dent demand
Biotech firm Bio-Techne on Wednesday missed Wall Street estimates for third-quarter revenue, as cuts to U.S. academic funding weighed on demand for its drug-development products.
Track Bio-Techne and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Bio-Techne competitors & trending companies
Browse news for competitors to Bio-Techne and other trending companies.
Agilent
Thermo Fisher
Diasorin
Revvity
Proteintech
PerkinElmer
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio